In the manufacture of injectable solutions, the selection of terminal sterilisation versus aseptic processing is determined by the thermal degradation kinetics of Triquin in aqueous media. Forced degradation samples held at 80 °C, 100 °C, and 121 °C for 30 to 120 min are analysed by HPLC-DAD; if assay loss exceeds 0.5% per hour at 121 °C, terminal steam sterilisation is rejected in favour of aseptic filtration. Prior to filling, the bulk solution is passed through a 0.45 µm PVDF pre-filter and a 0.22 µm nylon 66 sterilising-grade membrane, with filter integrity confirmed by a diffusion test per ASTM F838-20. The filling line, consisting of a 316L stainless steel mixing vessel, a rotary piston pump, and a laminar airflow tunnel meeting ISO 14644-1 Class 5, is qualified by media fill. Sub-visible particle loads are controlled to USP <788> limits: for small-volume parenterals, 6000 particles per container at ≥10 µm and 600 particles per container at ≥25 µm. Osmolality of the finished solution, measured by freezing point depression per USP <785>, is adjusted with sodium chloride or mannitol to an operational window of 280–320 mOsm/kg. pH is stabilised with citrate or phosphate buffer in the range of 4.5–7.5, depending on API solubility and injection site tolerance. The batch release specification includes sterility per USP <71>, bacterial endotoxin per USP <85> at not more than 0.5 EU/mg of API, and visible particulate inspection per USP <790>. Published stability data for Triquin veterinary injection at high concentration are limited; therefore, a bracketing stability protocol under VICH GL3 is recommended for each container-closure system.

What Limits Blend Uniformity in Low-Dose Triquin Tablets?

Low-dose tablet manufacture for Triquin is constrained by the risk of segregation and by the propensity of magnesium stearate to form hydrophobic films at extended lubrication times. When the active content is below 5 mg per unit, the API is pre-blended with lactose monohydrate NF or microcrystalline cellulose NF in a 1:3 or 1:5 ratio using a 600 L bin blender operated at 12 rpm for 10 min. Blend uniformity is assessed by stratified sampling across 10 positions following the FDA guidance for powder blends; the acceptance criterion is an RSD of not more than 5.0%. Direct compression is feasible only if the API has a Carr Index below 25 and a Hausner Ratio below 1.25; otherwise wet granulation or roller compaction is required. If wet granulation is used, the end point is controlled by impeller power consumption in a high-shear granulator, with an LOD after fluid-bed drying set to 1.5–2.5% w/w. Over-lubrication above 1.0% w/w magnesium stearate, or blending for more than 20 min, has been shown to increase disintegration time above the 15-minute limit for uncoated tablets in USP <701> and to reduce dissolution below the Q value of 80% at 30 min in USP <711>. Compression is performed on a 10-station rotary press with tooling designed for 6 mm round concave tablets; compression force is adjusted to 8–20 kN to achieve a diametral breaking force of 40–80 N, measured according to USP <1217>. Ejection forces above 1200 N due to over-dried granulation below 1.5% LOD can cause edge chipping and punch scoring. Table 1 summarises the compendial release methods applied to solid Triquin dosage units.

Capsule Formulation Boundaries and Shell Compatibility

Because gelatin shells exchange water with the fill matrix, the first processing constraint for Triquin capsule fills is shell moisture. Gelatin capsule shells are specified at 12.5–16.0% w/w water content by loss on drying; filling of formulations below 2.0% w/w water can extract plasticising water from the shell and produce brittle capsules that crack during sorting. HPMC shells, with a shell moisture in the range of 2.0–6.0% w/w, are selected when the API or excipients are moisture-sensitive. Powder blends for capsules require a minimum bulk density of 0.45 g/mL and a tapped density of 0.60 g/mL to achieve consistent fill weights on a dosing-disc machine; lower bulk density increases fill weight RSD above 4.0%. Lubricant levels are kept below 0.75% w/w and blending time below 10 min to avoid reduction of dissolution rate. The dissolution test for Triquin capsules uses USP <711> Apparatus 2 at 50 rpm in 900 mL pH 6.8 phosphate buffer; the acceptance criterion is not less than 75% at 45 min for immediate release unless the veterinary monograph specifies otherwise. Empty-capsule dimensions and fill weight are verified against a capsule sorter with a 2% weight rejection threshold. The capsule shell and fill formulation are challenged at 25 °C/60% RH and 40 °C/75% RH for 6 months in open containers to detect water migration or shell softening before the stability study is initiated.

High-shear granulation of Triquin intermediates uses torque or power consumption as the primary endpoint control variable because time-based addition alone produces batch-to-batch density drift. On a 300 L high-shear mixer, water addition is ramped from 8% to 14% w/w of dry mass while monitoring the impeller power draw; the wet mass is discharged at the power plateau and dried in a fluid-bed dryer with inlet air at 60 °C to an LOD of 1.5–2.5% w/w. Dried granules are screened through a 1.0 mm sieve. The resulting particle size distribution targets a D50 of 150–450 µm and a D90 below 800 µm for acceptable flow into sachet filling lines. Flowability is assessed per USP <1174>; a Carr Index above 25 or a Hausner Ratio above 1.25 indicates the need for glidant correction with colloidal silicon dioxide at 0.2–0.5% w/w. Dry granulation by roller compaction is used when the API exhibits hydrolytic or thermal instability; in that case, compacts are milled at 60 rpm with a screen size of 0.8 mm to yield dense granules. Granule assay is checked at three strata of the storage bin because segregation of fines can create potency drift exceeding 5.0% if the bin is not designed with a steep wall angle above 60°.

When Triquin Powder Is Filled Into Unit-Dose Sachets at Ambient Humidity

In a humidity-controlled suite, powder filling for Triquin oral powders is performed because static adhesion increases hopper residence time and fill weight drift when the ambient dew point exceeds 12 °C. The powder blend is specified with a water content below 2.0% w/w by USP <921> Method Ia before loading. Sachet forming and filling on a horizontal form-fill-seal machine at 40–60 strokes per minute requires a powder with a flow function coefficient above 4.0 measured by ring shear tester per ASTM D6773. If the FFC falls below 4.0, 0.2% w/w fumed silica is introduced by low-shear dilution. Particle size distribution is controlled to a D90 below 250 µm for rapid dispersion in drinking water. In dispersion testing, a sachet content is emptied into 1 L water at 25 °C and stirred at 100 rpm; complete dispersion within 60 seconds is regarded as the development target, though no harmonised pharmacopoeial acceptance criterion exists for veterinary oral powders. Cross-contamination between batch runs is controlled by swab sampling of product-contact surfaces after cleaning, with acceptance not more than 10 ppm of the next product, validated according to 21 CFR 211.67. Sampling points include hoppers, augers, fill heads, and sealing jaws; the dominant failure mode is active residue accumulating behind the sealing jaw heater plates where cleaning-in-place nozzles do not reach.

Carry-over control determines premix line feasibility.

Triquin premix production in a multi-species feed mill is governed by carry-over retention on equipment surfaces rather than by blend uniformity alone. Premix concentrates are blended at 2.0–10.0 g/kg of carrier in a ribbon or paddle mixer with a batch volume of 500–2000 L. Homogeneity of the premix is assessed by taking 10 samples and measuring content; the coefficient of variation should be not more than 5.0% for a Type A medicated article under 21 CFR 558.5. The carrier is ground limestone, wheat middlings, or rice hulls; limestone buffers pH above 8.0 and can accelerate base-sensitive degradation, so a 90-day accelerated stability study at 40 °C/75% RH is run before use. Cleaning between batches in a feed mill is not a wet process; flush-outs with 100–250 kg of ground corn or wheat bran are performed, with subsequent quantitative LC-MS/MS verification at the discharge point. Bucket elevators and drag conveyors can retain 2–5% of the previous batch mass without adequate purging; this has been documented on production-scale lines handling 5-tonne batches. The limit for carry-over of active into a non-target feed is commonly set at not more than 1.0% of the lowest therapeutic concentration, but for Triquin the exact value is derived from target animal safety data per VICH GL6. Feed mill sequencing places Triquin premix after flushing batches and before low-risk feed; manual override of batch records has been a repeated deviation in audit reports under 21 CFR 211.67.

Because aqueous and co-solvent solutions place the API in direct contact with water, buffers, and preservatives, chemical stability rather than blend uniformity becomes the controlling variable. Aqueous solutions are buffered to pH within ±0.2 units of the pH of maximum stability; if no published pH-rate profile exists, a multifactorial design is executed at pH 2.0, 4.0, 6.0, and 8.0 with ionic strength held at 0.1 mol/L. Co-solvents such as propylene glycol or glycerin are used at 10–30% v/v to suppress hydrolysis, but the addition of greater than 30% v/v propylene glycol can increase viscosity and reduce filter flux through 0.22 µm membranes. Antioxidants, for example sodium metabisulfite at 0.1% w/v and ascorbic acid at 0.05% w/v, are effective only when the solution is blanketed with nitrogen and the headspace oxygen is below 1.0% v/v. The solution is filled into amber Type II glass vials or high-density polyethylene bottles that meet Ph. Eur. 3.1.3 or Ph. Eur. 3.1.5; leachable screening is performed by storing the final packaged solution at 40 °C/75% RH for 3 months in inverted orientation. Assay, pH, colour, clarity, and preservative content are measured at 0, 1, 2, and 3 months. The release specification includes a preservative efficacy test per Ph. Eur. 5.1.3 or USP <51>, with acceptance criteria of not less than a 1.0 log reduction at 7 days for bacteria and not less than a 1.0 log reduction at 14 days for fungi. If the product is intended for multiple-dose injection, the container closure must maintain sterility after 100 punctures and the elastomer must comply with Ph. Eur. 3.2.9.